-
3m 54s
-
7m 18sPart 1 Welcome & Programme Overview
-
1h 1m 14s
-
44m 41sPart 3 | Session 1 Critical Moments in Obesity: Early Decisions That Alter Cardiometabolic Risk
-
1h 28m 7sPart 3 | Session 2 Preventing Irreversible Organ Damage: Treating Progressive Obesity
In this CV-focused track, Nikolaus Marx (Aachen, DE), Naveed Sattar (Glasgow, UK), Erin Michos (Baltimore, US) and James Burton (Leicester, UK) explore how obesity drives cardiovascular and kidney disease progression, highlighting opportunities for earlier intervention, risk stratification and disease modification.
Presentations:
- Obesity as an Accelerator of CKM Disease – Nikolaus Marx
- Evidence for Disease Modification and Outcomes – Naveed Sattar
- Kidney Protection is Central, Not Secondary – James Burton
- Imaging and Risk Stratification in Established CKM Disease – Erin Michos
New Horizons in Obesity Management returned on 17 June 2026 for its third edition, bringing together leading international experts to explore obesity as a central driver of cardio-kidney-metabolic (CKM) disease and a key contributor to multimorbidity across organ systems.
Through a series of practical, evidence-based sessions, faculty examined the latest science, clinical data and treatment strategies shaping modern obesity care. The programme introduced three dedicated specialty tracks – cardiology, primary care and obesity-focused practice – allowing attendees to follow the learning pathway most relevant to their clinical practice or explore the full spectrum of content on demand. Across the sessions, experts discussed lifestyle, pharmacological and procedural approaches, with a focus on translating emerging evidence into real-world patient care.
Led by course directors Dr Angela Fitch (Knownwell, Boston, US), Prof Richard Hobbs (University of Oxford, Oxford, UK) and Prof Nikolaus Marx (University Hospital Aachen, Aachen, DE), the programme featured a distinguished global faculty and explored how earlier intervention, multidisciplinary collaboration and evolving obesity therapies can improve outcomes across the CKM continuum.
Watch the full on-demand series* to catch up on the latest insights, practical guidance and expert discussion from the event.
*Please note, the live version of New Horizons in Obesity Management was accredited. The on-demand version is not.
The symposium 'Real-World Decisions: Implementing Disease-Modifying Obesity Therapy in Primary Care' is available to watch via the link below:
Learning Objectives
- Discuss how obesity drives risk for CKM diseases
- Explain the biological links between obesity and CKM diseases
- Assess how modern obesity medications may modify disease and improve CKM outcomes
- Apply multidisciplinary, translational strategies to improve patient outcomes
- Implement practical strategies to support long-term disease modification and sustained weight loss in real-world settings
- Identify gaps in current care and evaluate emerging therapeutic targets from ongoing clinical trials
Target Audience
- Cardiologists
- Diabetologists
- Endocrinologists
- Nephrologists
- Nurses
- Obesity Specialists
- Primary Care Physicians
More from this programme
Part 1
Welcome & Programme Overview
In this welcome session, Richard Hobbs (Oxford, UK), Angela Fitch (Boston, US) and Nikolaus Marx (Aachen, DE) introduce the programme, share the key learning objectives and outline the clinical priorities shaping the future of obesity management.
| 1 session | |
| Welcome & Programme Overview | Watch now |
Part 2
Session 1 | The CKM Axis Begins With Obesity
In this foundational session, Nikolaus Marx (Aachen, DE), Angela Fitch (Boston, US), Harold Bays (Louisville, US) and Naveed Sattar (Glasgow, UK) examine obesity as the starting point of CKM disease, exploring its biological impact, cardiovascular consequences and evolving treatment strategies.
Part 3
Session 2 | Translating CKM Mechanisms Into Clinical Practice
In this interactive track-based session, expert faculty translate the mechanisms of CKM disease into practical clinical decision-making, exploring how obesity can be addressed across the continuum of risk, from early intervention and risk modification to advanced organ disease management. Choose to follow the pathway most relevant to your practice, or watch all three tracks, led by course directors Richard Hobbs (Oxford, UK), Angela Fitch (Boston, US) and Nikolaus Marx (Aachen, DE).
Part 4
Session 3 | From Silos to Strategy: Coordinating Obesity Care
In this collaborative session, the course directors bring the three specialty tracks back together, exploring how obesity care can be coordinated across disciplines to support timely intervention, aligned decision-making and better outcomes across the CKM continuum.
Part 5
Session 4 | Precision Obesity Care: Biomarkers, Data and the Next Wave of Therapies
In this forward-looking session, Harold Bays (Louisville, US) and Naveed Sattar (Glasgow, UK) explore the next generation of obesity management, examining emerging therapies, combination treatment strategies and the evolving role of biomarkers in personalised cardiometabolic risk assessment.
Part 6
Session 5 | From Evidence to Access: Implementing Obesity Care Across Health Care Systems
In this interactive panel session, Richard Hobbs (Oxford, UK), Luc Van Gaal (Antwerp, BE), Erin Michos (Baltimore, US), Sean Wharton (Toronto, CA) and Ozden Gokdemir (Izmir, TR) discuss the real-world challenges of implementing obesity care, exploring how evidence can be translated into equitable access across different healthcare systems.
Part 7
Session 6 | From Intervention to Impact: Creating a Sustainable Obesity-CKM Ecosystem
In this penultimate session, Nikolaus Marx (Aachen, DE), Richard Hobbs (Oxford, UK), Angela Fitch (Boston, US) and James Burton (Leicester, UK) explore how to build a sustainable obesity–CKM care model, focusing on long-term prevention pathways, organ protection and integrated cardio-kidney management.
Part 8
Key Takeaways and Closing Remarks
In this closing session, the course directors reflect on the key insights and practical takeaways from across the programme, highlighting priorities for advancing obesity management and CKM care in clinical practice.
| 1 session | |
| Key Takeaways and Closing Remarks | Watch now |
Faculty Biographies
Nikolaus Marx
Professor of Medicine
Prof Dr Marx is a distinguished Professor of Medicine and Cardiology at the RWTH University Hospital Aachen, Germany. His clinical and research interests are centrally focused on cardiovascular disease in patients presenting with significant comorbidities, including Type 2 diabetes mellitus and chronic kidney disease. Prof Marx is a recognised authority on the interplay between metabolic disorders and cardiovascular health. He has contributed significantly to clinical guidelines and trials in this domain, making him a prominent figure in bridging diabetology and cardiology, and frequently serving as faculty at major international congresses.
James Burton
Professor of Renal Medicine
Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.
In addition Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.
He is the current Chair of the UK Kidney Association Clinical…
Naveed Sattar
Professor of Metabolic Medicine
Prof Naveed Sattar is a distinguished Professor of Metabolic Medicine at the renowned Institute of Cardiovascular and Medical Sciences, University of Glasgow. With over two decades of dedicated research and clinical experience, Prof Naveed Sattar has emerged as a leading figure in the field of metabolic medicine and cardiovascular health.
Prof Naveed Sattar's research delves into the origins, evaluation, and treatment of diabetes, obesity, and cardiovascular conditions. Collaborating with various colleagues over the past two decades, he has authored numerous impactful papers, notably with the Emerging Risk Factor Consortium and diabetes registries in Scotland and Sweden. Prof Naveed Sattar has contributed to several lifestyle-focused trials, such as DIRECT, EUROFIT, and UPBEAT, producing mechanistic insights alongside.
Erin D Michos
Associate Professor of Medicine and Director of Women's Cardiovascular Health
Dr Erin Michos is an Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women’s Cardiovascular Heath and Associate Director of Preventive Cardiology with the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Dr Michos is an internationally known expert in Preventive Cardiology and Women’s Health and has authored over 350 publications. Her research has focused on cardiovascular disease among women; coronary artery calcium, inflammatory markers, and other novel biomarkers of cardiovascular risk; lipids; and vitamin D and other supplements. She is an Associate Editor for Circulation and the American Journal of Preventive Cardiology.
Following receipt of her medical degree from Northwestern University, Dr. Michos…